cyrilzakka/clinical-trials huggingface dataset:
Lutein Absorption in Healthy Adults

This study will evaluate the absorption of lutein when consumed in different oil blends.


Eligibility Criteria:
Inclusion Criteria:

Subjects will be eligible for the study if they meet all of the following inclusion criteria:

* BMI ≥ 18 and ≤ 25 kg/m2
* Between 18 and 45 years of age, inclusive
* Male or a non-pregnant, non-lactating female, nulliparous or at least 6 weeks postpartum prior to screening visit. A urine pregnancy test is required for all female subjects unless she is not of childbearing potential. If female is of childbearing potential, is practicing one of the following methods of birth control (and will continue through the duration of the study):

  * Condoms, sponge, diaphragm or intrauterine device;
  * Oral or parenteral contraceptives for 3 months prior to screening visit;
  * Vasectomized partner;
  * Total abstinence from sexual intercourse.
* If on a chronic medication, subject has been on constant dosage for at least two months prior to screening visit

Exclusion Criteria:

Subjects will be excluded from the study if they meet any of the following criteria:

* Current smoker
* Current chronic disease, including malabsorption or gastrointestinal disorders; hyperlipidemia; anemia; hemophilia; excessive bleeding; cystic fibrosis; kidney disease requiring dialysis; diabetes; active malignancy; wasting condition
* Current chronic contagious, infectious disease, such as active tuberculosis, Hepatitis B or C,or HIV
* Vegetarian, or has very selective food habits/dieting
* Average intake of alcoholic beverages greater than 2 drinks per day
* Medication or dietary supplement use to lower plasma lipids or affect lipid absorption or transport, including antibiotics
* Supplement use that contains carotenoids (multi-vitamin as an example)
* Known allergy or intolerance to any ingredient found in the study products
The Performance of the Mologic Biomarker Panel in Infection

This study is a prospective, single center, observational, cohort study of patients to determine whether the Mologic Biomarker Panel can identify patients with infection from those without, including those with other reasons for inflammation (e.g. post-operative). It will also assess whether it has the potential to judge the severity of illness, prognosticate outcome and guide antibiotic therapy.

The aim is to recruit patients who are "representative" of patients with suspected sepsis, uncomplicated infection, or non-infection related critical illness that require critical care intervention and assessment.

This study is observational and will not alter patient management or the standard of care. The results from the investigational Mologic Biomarker Panel and associated research assays will not be provided to treating clinicians, or used in any manner to affect patient care.

The study will take place over approximately an 18-month period and it is anticipated that approximately 600 patients will be collectively enrolled. The study aims to recruit patients from three environments within UCLH:

* The Emergency Department.
* Critical Care Unit
* Patients undergoing major surgery


Eligibility Criteria:
Inclusion Criteria:

* ≥ 18 years old
* Investigated for potential infection (the clinical need for a blood culture)

Exclusion Criteria:

* \<18 years old
* Severe anaemia (\<60g/dl) and contra-indication to transfusion
* Unable to gain consent or agreement
* Treated with palliative intent
* Blood culture indicated for screening or monitoring
Motor Learning of a Planning Task in Stroke Patients: the Maze Paradigm Measured Through Time and Error as Variables

The purpose of this study is to investigate the process of acquiring a motor skill subject in post-stroke, comparing them with healthy subjects.

20 post-stroke patients were comprised to the experimental group (EG) and 20 health subjects were included to the control group (CG. Inclusion criteria: chronic stroke, single stroke event, lesion in anterior circulation, right handed subjects, MEEM over 23 points. The task consisted in a maze paradigm, made by pencil and paper, with the non affected side for EG and left upper extremity for CG. The instruction was given to the subjects to complete the task as fast as possible. The study consisted in three phases: acquisition (AQ)with 30 trials, transfer (TR, short retention (R1)and long term retention (R2 both with 5 trials.

Eligibility Criteria:
Inclusion Criteria:

* Age between 40 and 65
* Injury in territory of movement earlier, as shown by examination of image and finding medical neurologist
* Time of injury over 6 months
* Single vascular event
* Right handed, by applying the Inventory of Dominance Side of Edinburgh Mini mental with scores over 23 points

Exclusion Criteria:

* Aphasia of understanding
* Instability clinic
* Other neurological diseases associated (Parkinson's disease, dementias, Alzheimer)
Staining in a Healthy, Non-Dry Eye Population

The clinical objective of this study is to quantify the levels of corneal and conjunctival staining in a healthy, non-dry eye population. This is a descriptive study without test article administered.


Eligibility Criteria:
Inclusion Criteria:

* Healthy eyes

Exclusion Criteria:

* Age related
Short-term Effects of Carbohydrate-restricted Diet on Glycemic and Metabolic Control Among Children and Adolescent With Type 1 Diabetes Mellitus

The current management of type 1 diabetes mellitus (T1DM) involves the use intensive insulin therapy, frequent blood glucose monitoring and carbohydrate counting.

There is a need to strengthen some of the T1DM management aspects as dietary intervention in order to achieve better glycemic and metabolic control.

The international society for pediatric and adolescent diabetes (ISPAD) recommend that children and adolescents with T1DM have about 50% of their total daily caloric requirement from carbohydrates. However, an alternative approach is emerging in recent years. The use of low-carbohydrate diet is suggested to reduce postprandial hyperglycemia and glycemic variability and lower the required insulin.


Eligibility Criteria:
Inclusion Criteria:

* Children and adolescents aged 10 - 18 years, diagnosed with T1DM for at least 1 year attending the Pediatric diabetes clinic at Sohag University Hospital and using the MDI regimen and carbohydrate counting methods are eligible for the study.

Exclusion Criteria:

* Children and adolescents with associated diseases such as autoimmune hypothyroidism or celiac disease and those with diabetes-related complications such as diabetic neuropathy, retinopathy or nephropathy will be excluded.
Comparison on Radiotherapy Permanent Skin Marking With Lancets and an Electric Marking Device

Comparison on radiotherapy skin set-up markings with lancets versus Comfort Marker 2.0®

A Prospective, unicentric, randomized, controlled, parallel, double-blinded, cohort study comparing radiotherapy skin set-up markings with lancets versus electric marking device (Comfort Marker 2.0® by CIVCO®)

Eligibility Criteria:
Inclusion Criteria:

* Age at least 18 years old.
* Patients referred to our department to receive external beam radiation therapy.
* Eastern Cooperative Oncology Group performance status of 0 to 1.
* Estimated fractionating schedule of at least 13 once-daily fractions.
* Written informed consent.

Exclusion Criteria:

* Patients requiring either immobilisation thermoplastic masks (for head or head and shoulders) or vacuum cushion.
An Investigation to Validate Speech Perception Assessment for Adult Cochlear Recipients Using a Mobile Research App

The study is a feasibility, prospective, repeated-measures, multi-country, multi-centre, study of the Mobile Research App to measure and validate speech perception endpoints in adult cochlear implant recipients.


Eligibility Criteria:
Inclusion Criteria:

* Adults 18 years of age or older.
* Uses a hearing device or devices (hearing aid/s and/or cochlear implant/s).
* Fluent speaker in the language used to assess clinical performance as judged by the investigator.
* Willing and able to provide written informed consent.

Exclusion Criteria:

* Unable or unwilling to comply with the requirements of the clinical investigation as determined by the Investigator.
* Investigator site personnel directly affiliated with this study and/or their immediate families; immediate family is defined as a spouse, parent, child, or sibling.
* Cochlear employees or employees of Contract Research Organisations or contractors engaged by Cochlear for the purposes of this investigation.
* Currently participating, or participated within the last 30 days, in another interventional clinical investigation/trial involving an investigational drug or device (unless the other investigation was/is a Cochlear sponsored investigation and determined by the investigator or Sponsor to not impact this investigation).
* Women who are pregnant.
Study of the Vascular Disrupting Agent NPI-2358 in Patients With Advanced Solid Tumors or Lymphoma

This is a Phase 1 clinical trial examining the safety, pharmacokinetics and pharmacodynamics of escalating doses of the vascular disrupting agent NPI-2358 in patients with refractory solid tumors or lymphoma. The formation of new blood vessels (angiogenesis) is an important component of tumor growth and vascular disrupting agents are intended to target the differences between these tumor blood vessels and the blood vessels in normal tissues. NPI-2358 has also been seen to directly affect tumor cells.


Eligibility Criteria:
Inclusion Criteria:

* ECOG performance status ≤ 2
* Pathologically or histologically confirmed solid tumor malignancy
* Patients must not be candidates for regimens known to provide clinical benefit.
* All adverse events of any prior chemotherapy, surgery, or radiotherapy, must have resolved to National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE) (v. 3.0) Grade ≤ 2, except for neurological toxicity that must have resolved to Grade ≤ 1.
* Adequate bone marrow reserve, hepatic and renal function
* Signed informed consent

Exclusion Criteria:

* Administration of chemotherapy, biological, immunotherapy or investigational agent (therapeutic or diagnostic) within 21 days prior to receipt of study medication (6 weeks for nitrosoureas or mitomycin C; 12 weeks for radioimmunotherapy). Major surgery, other than diagnostic surgery, within 6 weeks before first study drug administration. Radiotherapy within 4 weeks (some types of radiation therapy are excluded regardless of interval since treatment).
* Significant cardiac history or findings
* Underlying conditions or medications associated with bleeding diathesis
* Disorders associated with significant vascular pathology
* Lung cancer with central chest tumors
* Prior treatment with vascular disruptive agents
* Seizure disorder requiring anticonvulsant therapy; prior transient ischemic attack or cerebrovascular accident
* Brain metastases
* Severe chronic obstructive pulmonary disease (COPD) with hypoxemia
* Active uncontrolled bacterial, viral, or fungal infection, requiring systemic therapy
* Known infection with human immunodeficiency virus (HIV), active hepatitis A, B, or C
* Patients with a prior hypersensitivity reaction to any product containing Solutol and/or propylene glycol
* Pregnant or breast-feeding women. Female patients must be postmenopausal, surgically sterile or they must agree to use acceptable methods of birth control. Female patients with childbearing potential must have a negative serum pregnancy test. Male patients must be surgically sterile or agree to use an acceptable method of contraception.
* Concurrent, active second malignancy for which the patient is receiving therapy, excluding basal cell carcinoma of the skin or carcinoma in situ of the cervix
The ATLAST Long-Term Study

The Study is a multi-center, prospective, open label, single-arm, three-month, long-term study of the Attune Sleep Apnea System for the treatment of obstructive sleep apnea (OSA). The objective of the study is to monitor long-term use of the Attune Sleep Apnea System.


Eligibility Criteria:
Inclusion Criteria:

* Subject participated in the ATLAST Study, and completed the 28-day take-home period
* Subject understands the Study protocol and is willing and able to comply with Study requirements and sign the informed consent form.
* The study physician and investigator believe that study participation is appropriate for the subject.
* Subject has at least one molar in each of the four quadrants of the mouth (right upper, right lower, left upper, and left lower).

Exclusion Criteria:

* Female subjects who are pregnant or intend to become pregnant during the study period.
* Poor nasal patency as evidenced by the inability to breathe through the nose with the mouth closed.
* Oral cavity infection or any other oral or dental condition or problem that would limit subject use of the Attune Sleep Apnea System
* History of any OSA surgical treatment
Chewed Versus Integral Pill of Ticagrelor

Hypothesis The primary question the investigators propose to answer is whether all patients undergoing percutaneous coronary intervention (PCI) with stent deployment who receive chewed ticagrelor will demonstrate more rapid drug absorption and decreased platelet reactivity as compared to integral pill form 1 hour after drug administration.

Hypothesis The primary question the investigators propose to answer is whether all patients undergoing PCI with stent deployment who receive chewed ticagrelor will demonstrate more rapid drug absorption and decreased platelet reactivity as compared to integral pill form 1 hour after drug administration.

Secondary Hypotheses:

1. Major adverse cardiac and cerebrovascular event (MACCE) rate at 30 days and 1 year.

   1. Death
   2. Repeat myocardial infarction
   3. Need for urgent revascularization
   4. Cerebrovascular accident
2. Rate of stent thrombosis and in-stent stenosis at 30 days and 1 year.
3. Bleeding: Defined as major, minor, or minimal bleeding based on thrombolysis in myocardial infarction (TIMI) criteria.

Eligibility Criteria:
Inclusion Criteria:

• All patients presenting to the cardiac catheterization lab for percutaneous coronary intervention.

Exclusion Criteria:

* Age \<18 years or Age \>89 years
* Known coagulopathy, bleeding diathesis, or active bleeding
* History of recent gastrointestinal or genitourinary bleed within 2 months
* Known chronic therapy with clopidogrel, prasugrel, or ticagrelor
* Major surgery within last 6 weeks
* History of intracranial bleed or intracranial neoplasm
* Suspected aortic dissection
* Severe hemodynamic instability, cardiogenic shock
* Life expectancy \<1 year
* Known severe liver or renal disease
* Known HIV treatment
* Any use of Glycoprotein inhibitors (GP IIb-IIIa) 48-hours before the procedure or any use during the procedure
* Any use of Cangrelor during or after the procedure
* Hemoglobin \<10 g/dL, platelet (PLT) \<100x10\^9/L
* Pregnancy
* Known allergy to study medication
Comparison of Refraction Measurments in Children Under General Anesthesia, With and Without Cycloplegic Drops

Assessment of refraction measurements in children under general anesthesia, with or without cyclopelgic eye-drops

Comparing to adults, children have high ability to preform accommodation of the intraocular lens, that is due to the Ciliary muscle. In order to measure children's refraction in an accurate way the Ciliary muscle must be paralyzed and that is usually done be cycloplegic eye-drops .In case a child is undergoing a medical procedure under general anesthesia the assumption that the Ciliary muscle is paralyzed (complete or partially) due to anesthetic medications. In this study we would like to compare the refraction measurements in children under who undergo general anesthesia before and after applying cycloplegic eye-drops. In this way we can learn about the effect of anesthetic medication on the Ciliary muscle.

Eligibility Criteria:
Inclusion Criteria:

1. 1 - 12 years old
2. Eyes that didn't underwent surgical procedure

Exclusion Criteria:

1. eye operation
Comparative Effect Of Percussive Therapy Device And Manual Myofascial Release Technique

The present study was concerned with the comparison of effect of Theragun PRO and manual myofascial release technique to improve Hamstrings Flexibility in healthy Adults. It was randomized clinical trial on two groups one got percussion therapy by theragun PRO and other got treatment through manual myofascial release technique. The outcome measure was hamstring flexibility.

Muscular flexibility is an important aspect of normal human function. Limited flexibility has been shown to predispose a person to reduce quality of life. Several studies developed protocols to improve flexibility of muscles, including manual myofascial release techniques, Stretching techniques or Percussive therapy. The studies about the effects of fascia relaxation and stretching techniques on flexibility reported that fascia relaxation increased flexibility of hamstrings. Many treatments likely combines the elements of a conventional massage and vibration therapy.

There is a lack of scientific evidence as to how and if percussive massage treatment affects ROM and muscle strength. To date, there are many studies on effect of percussive therapy on different muscle group, but investigators did not find work on hamstring muscle group. Therefore, it is aimed to find Comparative effect of Percussive therapy device and manual myofascial release technique to improve Hamstrings Flexibility in healthy Adults.

This was a Randomized clinical trial. Sample was taken through simple random sampling. Investigators will perform randomized clinical trial on two groups one got percussion therapy by theragun PRO and other got treatment through manual myofascial release technique. The outcome measure was hamstring flexibility.

Eligibility Criteria:
Inclusion Criteria:

* 18-35 years
* Male gender
* Traffic wardens with 5 years field experience
* Participants labeled by Orthopedic surgeon/Physician with reduced flexibility of hamstring muscle group (Unilateral or Bilateral)

Exclusion Criteria:

* Any history of Low back pain.
* Any traumatic History of lower extremity.
* Arthritis
* Sprain or Strain
Sensory Memory in Speech Motor Learning

The proposed studies focus on memory for speech movements and sounds and its relation to learning. Continuous theta-burst transcranial magnetic stimulation (cTBS) will be used to suppress activity in a region of pre-frontal cortex associated with somatic and auditory working memory (Brodmann area 46v) to test its involvement in learning.

This study will assess the relationship between sensory working memory and speech motor adaptation using a between subjects design. Participants will be assigned to one of two groups. Each group will undergo both auditory and somatosensory working memory tests. This will be followed by adaptation to altered auditory feedback. Using a different group of subjects, cTBS will be used to disrupt neural activity in Brodmann area 46v in ventrolateral prefrontal cortex to test its involvement in adaptation. One set of tests will focus on the effects of cTBS on both auditory and somatosensory working memory. A second set of tests will focus on the effects of cTBS on speech motor adaptation to altered auditory feedback. Both working memory and adaptation are assessed on 0 to 100 scales.

Eligibility Criteria:
Inclusion Criteria:

* right handed adults
* no known physical or neurological abnormalities

Exclusion Criteria:

* patients with:
* cardiac pacemaker
* surgical clips or values on the heart
* implants
* metal or metallic fragments in any part of the body
* pregnancy
* claustrophobia
* a personal or family history of epilepsy
* currently taking antipsychotic drugs
* currently taking antidepressant drugs
* currently taking antianxiety drugs
* history of concussion.
Therapeutic Exercise in Patients With Hemophilia

Objectives: To assess the efficacy of performing a therapeutic exercise program, compared with usual care, on pain relief, range of movement and self-perceived quality of life in patients with hemophilia

Design: Quantitative, experimental, longitudinal and prospective study.

Subjects: Male patients between 30 and 45 years old, with hemophilia type A or B and with knee, ankle or elbow arthropathy caused by hemophilia. Participants may be undergoing a pharmacologic treatment with intravenous VIII and/or IX factor

Methods: Participants in the experimental group will an intervention based on therapeutic exercise. One therapist will instruct the patients during two sessions (each lasting approximately 1 hour). Participants will be asked to continue this program at least twice a week. Meanwhile, those in the control group will receive usual physical therapy care, based on a more passive approach, including self-assisted joint mobilization and muscle stretching. Those in the control group will be also instructed to perform the protocol at home, at least twice a week. The intervention protocol in both groups will last three months


Eligibility Criteria:
Inclusion Criteria:

* Clinical diagnosis of hemophilia type A or hemophilia type B.
* Knee, elbow or ankle arthropathy caused by hemophilia
* Pharmacological treatment based on using VIII or IX factor concentrates.

Exclusion Criteria:

* Presence of VIII FIX inhibitors.
* Having received anti-inflammatory treatment using Arcoxia (Etoricoxib)
* Having undergone a surgical intervention at the target joint.
* Patients enrolled in other research which implies doing physical exercise.
Mean Platelet Volume and STEMI Clinical Risk Scores in Prediction of Impaired Myocardial Perfusion In Acute STEMI Patients Undergoing Primary Percutaneous Coronary Intervention.

Predicting no reflow in ppci of STEMI patients using mean platelet volume together with STEMI clinical risk scores


Eligibility Criteria:
Inclusion Criteria:

* patients presenting with acute STEMI, within 24 hours of symptoms, fulfilling criteria for PPCI protocol in our facility

Exclusion Criteria:

* patients presenting more than 24 hours of symptoms onset
* patients not eligible for PPCI program in our facility